#Navinfluorine investor presentation Q2fy21

Revenue 512 cr
High value business
H1FY20/H1FY21 - 253/332 ,increase 32%
Ebidta - 146 cr
Operating PBT - 125cr

H1FY21 revenue contribution from high value business - 65%

#Nifty #sensex #StockMarket #stocks
Revenue 308 cr
High value business Q2Fy20/Q2Fy21- 141/201 ,increase 42%
Ebidta 93cr
PBT 83cr


Legacy business 253/180 ,decrease 29%

High value business
253/332 ,increase 32%

Total revenue 506/512 ,increase 1%

Operating Ebidta 128/146

Speciality chemicals well balanced growth driven by life sciences & crop science segments

CRAMS Strong customer traction augurs well


Speciality business
180/199 ,increase 11%
CRAMS 72/133, increase 84%
High value business units 253/332,increase 32%
#crams #cdmo
Capacity expansion - High performance product (HPP)
$410 Mn (2800cr) contract signed with global company
$61.5mn(436cr) capex required
Contract period 7yrs,sales will be evenly staggered
Q4fy22 expected commencement of supplies
Project will be executed at Dahej
High performance product HPP is not part of Navin fluorine existing product portfolio,new set of oppurtunity for application of fluorine in a new vertical

Increase share of high value business, CRAMS & Speciality provide 65 % of topline

#navinfluorine #specialitychemicals
Focus on core business
Piramal pharma & #navinfluorine mutually agree on @PiramalGroup increasing its stake to 100% in convergence chemicals


• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with TheMarket🐝

TheMarket🐝 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @BullsforBears

31 Oct
@SyngeneIntl conference call transcript Q2FY21

Revenue from operations up 12%, 519 cr ,Ebidta 169 cr, PAT 84 cr
#COVID19 impacting operations of the company & its clients
Set up the busiest PCR testing center in Bangalore
Overall growth driven by discovery science,R & D center
Significant success for 2 clients
1)Albireo pharma - compound Odevixibat met primary endpoint in phase 3 for children suffering genetic liver disease
Syngene worked on registration batches to phase 3,helping in
regulatory filings

#pharma #Nifty
2) C4 therapeutics - biopharmaceutical company, novel therapy for cancer & neurodegenerative disease through Targeted protein degradation, recognized leader ,syngene conducted discovery research projects for C4 over last 3 years
#sensex #cdmo
Read 11 tweets
29 Oct
Piramal Q2 results update
28% increase in equity
39% reduction in debt D/E 0.96
12% YoY increase net profit 1124cr
No.of exposure >15% net worth of financial services - 1
Pharma arm valued EV of $ 2.7-3.1bn
CDMO revenue growth YoY 20%
@PiramalGroup #pharma #Nifty #sensex
India consumer product YoY growth +25%
Ebidta margin Q2fy21 23%
Net debt :
Mar'19 - 55,122cr
Oct'20 - 33457 cr
D/E - 2 to 0.96
Segment wise equity allocation
Financial 48%
Pharma 22%
Unallocated 23%

Equity of 25,000 cr for financial services to acquire oppurtunities
Consolidation in real estate picking pace - industry wise decline in number of developers since 2012 - 53%

Wholesale loanbook
Mar 19 - 51436cr
Sep 20 - 45840cr

Top 10 exposure
Mar 19 - 18404cr
Sep 20 - 14717cr,down by 20%
No.of account with> 15% net worth decreased frm 3 to 1
Read 6 tweets
25 Oct
@Mphasis financial result Q2fy21
Established as product challenger - ISG Next Gen Hybrid cloud data services 2020
AWS launch partner for airline,focus on healthcare,trade finance
Major contender as per Everest fr Cloud native Dev services 2020
New partnerships - Snowflake
Highest overall QoQ CC organic growth in over a decade
Highest quarterly revenue of $327.4mn ,crosses pre covid peak of Q4'20
Direct business : achieves $1bn annualized run rate

BCM : Consistent track record of double digit YOY growth
QoQ growth 17.4%,best in class
Insurance: QoQ overall growth 2.5% ,strong pipeline visibility
Broad based & strong growth across verticals in direct business
Europe grew 8.2% YoY in Q2'21 in CC,direct business Europe grew 23% YoY in CC
#innovation #AI #cybersecurity #IoT #sensex
Read 10 tweets
22 Oct
Speciality chemicals player
Promoters -Hemchand gala(original promoter),now Gogris of Aarti industries
Manufactures & markets Chlorophenols
Facility -fully integrated
Raw material - for Chlorophenol( Chlorine gas & phenol)
Chlorine easily available,phenol import
Industrial use for products in agrochemicals, dyes,pigments,pharma,veterinary,cosmetics

First SME IPO where MF took stake ,Reliance MF
Initially listed on SME platform,got listed on @bse in Sep 20 & @NSEIndia on 5th Oct20

Paying dividends since 2017
In 2017 company merged Abhilasha Tex chemicals into itself
Merger with Amarjyot chemicals expanded product portfolio to dues,pigments,pharma,agrochemicals

Drawbacks - Chinese players,top 10 clients contribute 75% business,sourcing of raw Material 80% from top 10 suppliers
Read 11 tweets
7 Oct
Nikunj dalmia in conversation with Saurabh Mukherjee on @ETNOWlive

@HDFCLIFE - brought big data to their life insurance business
More questionnaire compared to other insurance players
More rigorous health checkups
Better underwriting & embedded value due to big data use
Another player using big data @BajajFinCorp - superior ROE compared to other NBFCs

Move to complete digitization helping IT firms
@TCS reorients itself according to need of its fortune 500 clients ,moved from infrastructure software to application development to big data,cloud
@TCS ability to retrain lakhs of employees as per need is a big advantage

Next 3 months economic outlook to remain upbeat as Indis opens up
Small town real estate mkt is picking pace
Strong commentary from @HomeLoansByHDFC guided to strong recovery
Post lockdown pickup
Read 8 tweets
1 Oct
#RakeshJhunjhunwala on @ETNOWlive

1991 moment for Agriculture
Better pricing power for farmers
Structural reforms in transport & logistics sector to ramp up
India to be the pharma capital of the world
Underownwrship of equities in India
#Nifty #sensex #StockMarket
Percentage of corporate profits to GDP low in India
Api & generic companies to have both earnings & PE expansion
India focused pharma companies to have earnings but not PE expansion
Current pharma rally may last longer than previous rally
#Nifty #traders #stocks #markets
Electric vehicle adaptation in India will be faster than anticipated
Climate change to drive consumer behavior
Recovery from #COVID19 faster than expected
Oppurtunity in Infra,Hotels sector
Value stocks @ITCCorpCom @TheOfficialSBI to gain in 2nd phase of bull mkt
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!